Aprea Therapeutics Welcomes New Chief Medical Officer to Spearhead Clinical Pipeline Expansion
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced the appointment of Nadeem Q. Mirza, M.D., M.P.H., as its new Chief Medical Officer (CMO), effective May 1, 2024. Dr. Mirza, …
Aprea Therapeutics Welcomes New Chief Medical Officer to Spearhead Clinical Pipeline Expansion Read More